FDA Clearance Tracker · K193371
FreeStyle Libre 2 Flash Glucose Monitoring System
Last checked: Nov 19, 2026Latest source record: Jun 12, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Jun 12, 2020
Substantially Equivalent
Time to decision
190 days
Received Dec 5, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K193371
- Device name
- FreeStyle Libre 2 Flash Glucose Monitoring System
- Applicant
- Abbott Diabetes Care, Inc.
- Applicant location
- Alameda, CA
- Received
- Dec 5, 2019
- Decided
- Jun 12, 2020
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.1355
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QLG (Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K193371
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Abbott Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K233537 · Decided Apr 23, 2024 · 172 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K223435 · Decided Apr 13, 2023 · 150 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K222447 · Decided Mar 3, 2023 · 200 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.